For your convenience, we have created interactive editions of several investor documents and packed them into this eKit. These interactive documents are designed for comfortable reading and easy navigation.

Click here to access the investor kit.

Amgen - Recent Press Releases
08/27/15FDA Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab)Printer Friendly Version
08/25/15Amgen To Present New Long-Term Repatha™ (Evolocumab) Data Analysis At ESC Congress 2015Printer Friendly Version
08/25/15Amgen Submits New Drug Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416)Printer Friendly Version
08/18/15Amgen And University Of California, Berkeley Announce Multi-Year Partnership To Assist Cancer Patient Advocacy Organizations In Measuring Effectiveness Of ProgramsPrinter Friendly Version
07/30/15Amgen Announces Appointment Of Fred Hassan To Board Of DirectorsPrinter Friendly Version
07/30/15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57Printer Friendly Version
07/28/15Amgen Announces 2015 Third Quarter DividendPrinter Friendly Version
07/27/15Amgen Announces Webcast of 2015 Second Quarter Financial ResultsPrinter Friendly Version
07/24/15FDA Approves Kyprolis® (carfilzomib) For Combination Use In The Treatment Of Patients With Relapsed Multiple MyelomaPrinter Friendly Version
07/23/15Amgen Submits Supplemental New Drug Application For Kyprolis® (Carfilzomib) In Relapsed Multiple MyelomaPrinter Friendly Version